Full Press Release Details
Pharma Announces Closing of Initial Public Offering
Aviv, Israel, August 14, 2025 (GLOBE NEWSWIRE) - Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"),
a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions,
today announced the closing of its initial public offering of 1,250,000 ordinary shares ("Ordinary Shares") at a public offering
price of $8.00 per Ordinary Share. The gross proceeds of the offering were $10 million, prior to deducting underwriting discounts, commissions,
and other offering expenses. Nasus Pharma's shares began trading on the NYSE American LLC exchange on August 13, 2025 under the
ticker symbol "NSRX". Nasus Pharma has granted the underwriters an option for a period of up to 45 days from the date of
the final prospectus, to purchase up to an additional 187,500 Ordinary Shares at the initial public offering price, less the underwriting
discounts and commissions.
Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine
program, including, manufacturing scale-up and additional Phase 2 studies, and the remainder for general and administrative corporate
purposes, including working capital, and capital expenditures.
& Company (UK) Ltd. and Craft Capital Management LLC acted as Joint Bookrunners for the offering.
registration statement on Form F-1 (File No. 333-288582) (the "Registration Statement") relating to the initial public offering
was filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC on August 12, 2025. This
press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities referred to herein nor shall
there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or jurisdiction.
offering was made only by means of a prospectus forming a part of the Registration Statement. A copy of the final prospectus relating
to this offering has been filed with the SEC and copies of the final prospectus can be obtained by contacting Laidlaw & Company (UK)
Ltd., 521 Fifth Ave, 12th Floor, New York, NY 10075, or by calling 212-953-4900 or by e-mailing syndicate@laidlawltd.com.
Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions
in the community. NS002, Nasus's intranasal powder Epinephrine product candidate is being developed as a needle-free alternative
to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which
rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal ("PBI")
technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity's rich vascular network for quick absorption.
The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to
liquid-based nasal products.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things:
statements related to the expected use of proceeds from the Company's initial public offering. Forward-looking statements contained
in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section
titled "Risk Factors" in the final prospectus related to the initial public offering filed with the SEC. Forward-looking
statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except
as required under applicable law.
Nasus Pharma Ltd. Israel